Navigation Links
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Date:2/3/2009

y. The primary efficacy endpoint of the study was the increase in mean daily "ON" time ("ON" time without dyskinesia plus "ON" time with minor dyskinesia) during an 18-hour period as assessed by patients' recordings on diary cards.

Out of the 669 randomized patients, 89% of patients treated with safinamide completed the study (91% in the 50 mg dose group and 87% in the 100 mg dose group) compared to 89% in the placebo group. Over 90% of patients who completed the initial 24 weeks of treatment elected to enter a 78-week, placebo-controlled double-blind extension study, which is ongoing, to specifically assess the effect on dyskinesias as primary endpoint.

Secondary efficacy endpoints of this study were also met, including decrease in daily "OFF" time, decrease in mean "OFF" time following first morning dose of levodopa, mean change from baseline in the Unified Parkinson's Disease Rating Scale (UPDRS)(2) Section III (motor) score during "ON" time and mean change in Clinical Global Impression of severity of disease and change from baseline (CGI)(3). The incidence of dropouts, serious adverse events or clinically notable events among the three groups of the study were comparable.

Full study results after completion of ongoing analyses will be submitted for presentation at upcoming scientific meetings.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson's disease, Alzheimer's disease and other therapeutic applications, as per the agreement signed with Newron in 2006.

About safinamide

Safinamide, an alpha-aminoamide derivative that is orally formulated, is currently being developed by Merck Serono and Newron as an add-on treatment for patients with Parkinson's disease. Safinamide is believed to have a novel dual mechanism of action based on the enhancement of the dopaminergic function (through reversible inhib
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
3. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
11. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 The potential of the ... of therapeutic agents has been receiving undeniable attention with ... significant promise. The crucial formulation considerations for orally inhaled ... a major role in the efficiency of pulmonary delivery, ... of new formulation techniques and devices in recent years. ...
(Date:5/23/2013)... May 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, ... Annual dbAccess Health Care Conference in Boston.   ... 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.  The ... Company,s website at http://www.neurocrine.com . If ...
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... At the 96th Scientific Assembly and Annual Meeting ... November 28 - December 2 in Chicago, Siemens ... will unveil the Biograph™ mMR*, the world,s first ... simultaneous data acquisition technology, currently undergoing clinical use ...
... Schizophrenia is a chronic and disabling brain disorder ... results in substantial medical and societal costs, in particular ... devastating health-related and social effects on people with the ... analysis from a longer-term clinical study presented at the ...
Cached Medicine Technology:Siemens Unveils Biograph mMR Whole-Body Integrated MR-PET System Capable of Simultaneous Data Acquisition 2Siemens Unveils Biograph mMR Whole-Body Integrated MR-PET System Capable of Simultaneous Data Acquisition 3Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 2Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 3Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 4Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 5Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 6
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... dedicated to brain cancer research and advocacy, comments on ... Extraterrestrial Physics, that shows incorporating cold atmospheric plasma into ... cells. , According to a Science Daily ... Extraterrestrial Physics (MPE), biologists and physicians demonstrated the “synergistic ...
(Date:5/25/2013)... Dubai, UAE (PRWEB) May 25, 2013 ... a LASIK surgery clinic in Dubai, has announced his ... iFS laser is the only FDA-cleared femtosecond laser proven ... both the safety and precision of LASIK. , “We ... The iFS Advanced Femtosecond Laser at our Dubai LASIK ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
(Date:5/25/2013)... Richmond, Virginia (PRWEB) May 25, 2013 ... bracelet that relieves pain in seconds for arthritis, tendinitis ... innovator in alternative pain relief products announced a ... seconds. The magnetic bracelet for pain relief is demonstrated ... for pain uses 5400 Gauss magnets and has customers ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... disparities in children; adolescents -ST. LOUIS, April 7 ... today that it awarded a $25,000 grant to ... Alexandria, Indiana to support the School Based ... the effects of inaccessible primary health care for ...
... disorder, study finds , , TUESDAY, April 7 (HealthDay News) ... associated with an increased risk of a vision-threatening complication ... fluid accumulation in the retina. , Glitazones are a ... as pioglitazone (Actos) and rosiglitazone (Avandia). , The U.S. ...
... The Detroit Wayne County Health Authority has begun ... expedite the screening and enrollment of prospective Medicaid ... by TriHealix, a health care technology firm based ... to connect uninsured patients to the right assistance ...
... Fla., April 7 To help facilitate ... professionals and,Hispanic patients, Transitions Optical has developed ... This free bilingual guide illustrates key steps ... between eyecare professionals and,their patients to help ...
... old song goes but violent video games, a new Tel ... teens who play them. , "As a father and brain ... and playing video games," says Dr. Uri Polat of Tel Aviv ... to carry out the new study. "What we see now is ...
... Nonprofit Expertise to National OrganizationSPRINGFIELD, Va., April 7 ... national organization dedicated to supporting those affected by ... it has selected Christine Brown to be its ... nonprofit management, program development, fundraising and advocacy relations ...
Cached Medicine News:Health News:Centene Foundation for Quality Healthcare Awards Grant to Community Health Center 2Health News:Certain Diabetes Drugs May Pose Eye Risk 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 3Health News:Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals 2Health News:Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals 3Health News:Violent video games can improve vision 2Health News:The National PKU Alliance Expands Leadership and Names Christine Brown as Executive Director 2Health News:The National PKU Alliance Expands Leadership and Names Christine Brown as Executive Director 3
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With tubular base ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: